Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenergic antagonist that relaxes smooth muscle in the bladder neck and prostate. It demonstrates selectivity for the α1A and α1D receptor subtypes, offering bladder-specific effects with less systemic vasodilation compared to non-selective α-blockers.
## Primary Indications
* Signs and symptoms of Benign Prostatic Hyperplasia (BPH).
* Off-label: Medical Expulsive Therapy (MET) for distal ureteral calculi.
## Adult Dosing
* **BPH:** 0.4 mg orally once daily.
* If no response after 2–4 weeks, the dose may be increased to 0.8 mg orally once daily.
* Max dose: 0.8 mg daily.
## Pediatric Dosing
* **Not indicated/established.** While occasionally used off-label for neurogenic bladder in specialized pediatric urology settings under specific protocols, it is not FDA-approved for pediatric use. Dosing is highly variable and requires expert clinical discretion.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary.
* **Hepatic Impairment:** Use caution in severe impairment; not recommended in patients with Child-Pugh Class C.
## Contraindications
* Hypersensitivity to tamsulosin.
* History of angioedema.
* Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) in patients who are known CYP2D6 poor metabolizers.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde), rhinitis, asthenia.
* **Serious:** Orthostatic hypotension (first-dose phenomenon), syncope, Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors:** (e.g., ketoconazole, clarithromycin, ritonavir) Increase tamsulosin exposure significantly.
* **PDE5 Inhibitors:** (e.g., sildenafil, tadalafil) Potential for additive blood pressure lowering effects; initiate PDE5 inhibitors at the lowest dose.
* **Antihypertensives:** Potential for additive orthostatic hypotension.
## Monitoring
* Monitor blood pressure periodically, specifically noting symptoms of orthostasis.
* Prior to initiating therapy, rule out prostate cancer.
* Assess for resolution or improvement of LUTS (lower urinary tract symptoms).
## Clinical Pearls
* **Administration:** Take 30 minutes after the same meal each day to ensure consistent bioavailability. Swallow capsules whole; avoid crushing or opening.
* **Surgical Risk:** Advise patients to inform their ophthalmologist of tamsulosin use prior to cataract or glaucoma surgery to prevent IFIS complications.
* **First Dose:** Caution patients regarding potential syncope or dizziness when rising from a sitting or lying position during initial therapy.
* **Onset:** Full clinical benefit in BPH may take up to 2–4 weeks of consistent dosing.
***
*Disclaimer: This information is for educational purposes only. Tamsulosin dosing and clinical standards may vary based on institutional protocols and updated clinical guidelines. Always consult current, full prescribing information and verify clinical decisions with a physician or regulatory database before prescribing or administering medication.*
